Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mesenchymal stem cell-derived exosomes (MSC-Exos) are a class of extracellular vesicles that serve as critical mediators of paracrine signaling, carrying a diverse payload of proteins, lipids, and nucleic acids (Signal Transduct Target Ther. 2020; 5: 202). The cell-surface and extracellular targets of these exosomes include a variety of receptors and matrix components on recipient cells, such as toll-like receptors, integrins, and cytokine receptors, which facilitate vesicle docking and internalization (Journal of Nanobiotechnology, 2021). By interacting with these targets, MSC-Exos can modulate key intracellular pathways, including the PI3K/Akt and MAPK/ERK cascades, to promote tissue repair and suppress inflammatory responses (Frontiers in Cell and Developmental Biology, 2021). In clinical research, these interactions are being leveraged to develop cell-free therapies for conditions like myocardial infarction, osteoarthritis, and acute kidney injury. The surface of MSC-Exos is characterized by specific markers such as tetraspanins (CD63, CD81, CD9) and MSC-associated proteins (CD73, CD90), which are essential for their biological activity and targeting specificity (Pharmaceutics, 2022). However, the complexity and heterogeneity of these surface interactions present significant challenges for standardization and targeted delivery in a therapeutic context. Furthermore, while generally considered safe, the potential for MSC-Exos to promote tumor growth or induce unwanted immune responses remains a subject of ongoing investigation (Frontiers in Oncology, 2020).
MSC-derived exosomes interact with extracellular targets via ligand-receptor binding, direct membrane fusion, and endocytosis to deliver bioactive cargo (miRNAs, proteins, lipids) that modulates recipient cell signaling pathways such as PI3K/Akt, MAPK/ERK, and NF-kB.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mesenchymal stem cell-derived exosome surface and extracellular targets (MSC-Exo targets).